Red Nucleus

Using our Learning & Development toolkits, your Global Marketing and Global Medical Affairs teams can deploy assets to regional colleagues to: ✨ Ensure your approved message is compliantly discussed with your targeted customers ✨ Create a scalable solution that can be used over time as launch plans progress globally ✨ Generate excitement and buy-in around your program materials Please contact the Red Nucleus Learning & Development team to hear about how our proprietary solutions for Worldwide Team Members can ensure a successful handoff to your colleagues. Create impactful interactions with your targeted healthcare providers with confidence. 🔴🧠 #medaffairs #MedicalCommunications https://lnkd.in/gvzAMZf5

Emily Ng, MSc, and Mitun Patel, MSc, from the Red Nucleus Market Access and Commercialization team will be presenting a their poster Evaluating Key Drivers for Patient Access and Pricing Trends in ATMPs across Germany, France, and the UK at ISPOR 2024. Don't miss this opportunity to gain crucial insights into the evolving landscape of Advanced Therapy Medicinal Products (ATMPs) in key European markets! Join us at the Poster Session on Monday, November 18, 2024, from 10:30 AM to 1:30 PM to explore the intricate relationship between clinical evidence requirements and HTA outcomes for ATMPs. Don't miss this opportunity to stay ahead in the rapidly evolving field of advanced therapies. Our experts will be available to discuss how these findings can impact your specific projects and challenges in ATMP development and commercialization. Ready to optimize your approach to ATMP market access and pricing strategies? Let's connect at ISPOR 2024 and schedule a meeting to explore how these insights can benefit your organization's pipeline and market access planning. 🔴 🧠 🔬 #ISPOR2024 #ATMP #MarketAccess #HealthcareInnovation #Reimbursement

Kate Cullen, PhD, MRes, and Isobel Owens-Smith, MSc, will be presenting on The Cost of Innovation: Evaluating the Evolution of Willingness-to-Pay for CAR-T Therapies in Germany at ISPOR 2024. Don't miss this opportunity to gain critical insights into the evolving landscape of CAR-T therapy reimbursement! Join us at Poster Session 5 on Wednesday, November 20, 2024, from 9:00 AM to 10:00 AM to explore the changing dynamics of CAR-T therapy pricing and reimbursement in Germany since 2018. Our analysis provides valuable insights into how the German market has adapted to these groundbreaking therapies since their introduction. Understanding these trends is essential for: • Developing effective pricing and market access strategies • Anticipating future reimbursement challenges for innovative therapies • Balancing innovation with healthcare system sustainability Don't miss this opportunity to stay ahead of the curve in the rapidly evolving field of cell and gene therapies. Our experts will be available to discuss how these findings can impact your specific projects and challenges. Ready to optimize your approach to innovative therapy development and commercialization? Let's connect at ISPOR 2024 and schedule a meeting to explore how these insights can benefit your organization. 🔴 🧠 🔬 #ISPOR2024 #CART #MarketAccess #HealthcareInnovation #Reimbursement

Isobel Owens-Smith, MChem, and Kate Cullen, PhD, will be presenting their poster "The Impact of Weight-Based Dosing on Pricing and Reimbursement Outcomes for Ultra-Rare Disease Treatments in the EU4" at ISPOR 2024! 📊 Don't miss this opportunity to gain valuable insights into how weight-based dosing uncertainty affects pricing and reimbursement outcomes for ultra-orphan treatments in key European markets. Visit us at Poster Session 4 to learn more and discuss how these findings could impact your market access strategy. Our team of experts will be on hand to answer your questions and explore potential collaborations. Ready to optimize your ultra-rare disease market access approach? Let's connect at ISPOR 2024 and schedule a meeting to dive deeper into your specific challenges and opportunities[. #ISPOR2024 #MarketAccess #RareDisease #Pricing #Reimbursement

Excited to announce that Red Nucleus Clinical is a proud patron of CNS Summit 2024! 🎉 Stop by our booth to meet our team and discover how you can: Revolutionize your research: Endpoint design meets video technology in clinical trials At Red Nucleus Clinical, we're pioneering the integration of video outcomes in clinical trials. Our expertise lies in using multimodal multimedia capture to rate and score clinical outcome measures, providing the framework and expertise you need to elevate your research. Don't miss this opportunity to explore how we can transform your clinical trials with cutting-edge video technology. See you at CNS Summit 2024! 🔴 🧠 🔬 #CNSSummit2024 #VideoOutcomes #Video #Clinical Trials

Flora Kakanou, MRes, will be presenting a cutting-edge poster at ISPOR 2024, "Synthetic Control Arms Data Driven by Artificial Intelligence: A Viable Alternative to Placebo Cohorts in Comparative Clinical Studies?" Don't miss this opportunity to gain valuable insights into the future of clinical trials! Join us at Poster Session 4 on Tuesday, November 19, 2024, from 4:00 PM to 7:00 PM to explore how AI is reshaping clinical trial methodologies, particularly in diabetes and oncology. Key Highlights: 🔮 Discover recent developments in AI-driven approaches for clinical trials 📕 Understand the evolving regulatory landscape, including FDA and EMA perspectives 🏫 Learn about the challenges and opportunities in meeting payer and HTA body expectations ➕ Gain insights on optimizing clinical research through AI-powered synthetic control arms This research is crucial for pharmaceutical companies looking to leverage AI in their clinical trial designs while navigating the complex landscape of regulatory approvals and payer requirements. Ready to revolutionize your clinical trial strategy? Let's connect at ISPOR 2024 and schedule a meeting to discuss how these findings can benefit your specific projects and challenges. 🔴 🧠 🔬 #ISPOR2024 #ArtificialIntelligence #ClinicalTrials #MarketAccess #SyntheticControlArms

We're excited to announce that the Market Access and Commercialization (MACS) team from Red Nucleus will be attending ISPOR Europe 2024 in Barcelona! Join us at booth 820 from November 17-20 to connect with our experts and discuss the latest trends in health economics and outcomes research. This is a fantastic opportunity to explore how we can help navigate market access challenges and enhance commercialization strategies. We look forward to seeing you there! 🔴 🧠 🔬 #ISPOREurope2024 #MarketAccess #HEOR #RedNucleus

If you're looking for upcoming meeting support, fresh ideas, or ways to engage your team effectively, let’s partner to create extraordinary results. 💡 20+ interactive workshops covering communication, negotiation, leadership, and more. 🎯 Our focus? Turning potential into performance. 🔄 Flexible delivery options: live, virtual, or blended. 🧠 Reinforcement tools to ensure lasting impact. At Red Nucleus, we're transforming teams with our cutting-edge training programs. From seamless communication to innovative leadership, we're equipping professionals to excel in today's fast-paced industry. Whether you're in sales, medical affairs, or leadership, our tailored programs are designed to elevate your team's capabilities and foster a culture of excellence. 🔴 🧠 🔬 #LifeSciences #ProfessionalDevelopment #EssentialSkills #RedNucleus #BOLDtraining

Red Nucleus is at WODC EU 2024 in beautiful Barcelona! 🌟 Stop by our booth to discover how we are Redefining Patient Access with our cutting-edge video endpoint solutions. This is a fantastic opportunity to learn about our innovative approaches that enhance patient engagement and streamline healthcare delivery. 🎉 Additionally, don’t miss your chance to pick up an invitation to our exclusive cocktail event on Thursday night! Join us for an evening of networking and insightful discussions. We look forward to seeing you there! #WODCEU2024 #RedNucleus #PatientAccess #HealthcareInnovation

Last Thursday we reached another pivotal step in Red Nucleus’ exciting journey – a majority investment from Boston-based private equity firm, THL Partners. Mike Menta, an industry veteran of 20+ years, has joined us, assuming the role of Chief Executive Officer. Working very closely with Mike is our very own Ian Kelly, who is also transitioning into an exciting new role: Chief Relationship officer. Mike will be steering us to new heights, championing the “Red Glove Service” our clients have come to expect from us, while Ian will focus on strengthening customer and employee engagement. Ian will also serve as Vice Chairman of the Board of Directors, helping to shape and augment the services we provide to our customers around the world. We’re looking forward to what the next chapter brings. In particular, to making investments in our business and teams, to enable us to enhance our suite of service offerings across the pharmaceutical product lifecycle. Thank you to everyone who has been part of this incredible journey so far. Together, we will continue to innovate and drive success for our clients and our team! #RedNucleus #Leadership #CustomerEngagement #CompanyCulture #THLPartners #NewBeginnings